Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 3, Pages 492-499Publisher
SPRINGERNATURE
DOI: 10.1038/bjc.2015.226
Keywords
SIRT4; colorectal cancer; tumour suppressor; E-cadherin; invasion; epithelial-mesenchymal transition
Categories
Funding
- Ministry of Education, Culture, Sports, Science, and Technology
- Ministry of Health, Labor, and Welfare
- Kobayashi Cancer Research Foundation
- Princess Takamatsu Cancer Research Fund, Japan
- National Institute of Biomedical Innovation
- Osaka University Drug Discovery Funds
- Takeda Science and Medical Research Foundation
- Princess Takamatsu Cancer Research Fund
- Suzuken Memorial Foundation
- Yasuda Medical Foundation
- Pancreas Research Foundation
- Nakatani Foundation
- Nakatomi Foundation of Japan
Ask authors/readers for more resources
Background: SIRT4, which is localised in the mitochondria, is one of the least characterised members of the sirtuin family of nicotinamide adenine dinucleotide-dependent enzymes that play key roles in multiple cellular processes such as metabolism, stress response and longevity. There are only a few studies that have characterised its function and assessed its clinical significance in human cancers. Methods: We established colorectal cancer cell lines (SW480, HCT116, and HT29) overexpressing SIRT4 and investigated their effects on proliferation, migration and invasion, as well as E-cadherin expression, that negatively regulates tumour invasion and metastases. The associations between SIRT4 expression in colorectal cancer specimens and clinicopathological features including prognosis were assessed by immunohistochemistry. Results: SIRT4 upregulated E-cadherin expression and suppressed proliferation, migration and invasion through inhibition of glutamine metabolism in colorectal cancer cells. Moreover, SIRT4 expression in colorectal cancer decreased with the progression of invasion and metastasis, and a low expression level of SIRT4 was correlated with a worse prognosis. Conclusions: SIRT4 has a tumour-suppressive function and may serve as a novel therapeutic target in colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available